A fter age, sex is the most important risk factor for coronary artery disease (CAD), with women aged 35 to 74 years having 2 to 3 times lower myocardial infarction (MI) incidence than age-matched men. 1 The mechanism through which women are protected from MI/CAD is still largely unknown, but the observed sex difference and the fact that CAD risk in postmenopausal women approaches that of males suggests the involvement of the sex steroid hormone system. This hypothesis was initially supported by the results of observational studies that showed lower CAD risk among postmenopausal women undergoing hormone replacement therapy 2, 3 ; however, initial clinical trials of hormone replacement therapy have shown unexpected negative results, 4, 5 even unanticipated harm, al-though the timing of initiation of therapy may explain these conflicting results. 6 -8 
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The fact that CAD clusters in families 9 (estimated heritability 38% to 57% 10 ), coupled with the observation of sexand menopause-related differences in risk, suggests that inter-individual variation in CAD risk may be partly mediated by population-level genetic variation in the genes that encode elements of the sex steroid hormone system. ER␣ is an important signaling gateway within this system and is expressed in multiple cardiovascular tissues in both males and females. 11 The gene encoding ER␣, ESR1, has been the subject of several candidate gene association studies in relation to CAD over the past decade, with generally inconsistent results [12] [13] [14] ; however, only a very limited range of the genetic variation in ESR1 has been investigated, and the role of this gene in CAD risk remains to be clarified.
The last 5 to 7 years have seen a paradigm shift in our approach to investigating the genetic basis of complex diseases. Advanced new methods, including high-throughput genotyping, 15 genome-wide association studies (GWAS), 16 genotype imputation, 17 second-generation sequencing, 18 along with the availability of resources describing natural human genetic variation (eg, HapMap, 19 1000 Genomes Project 20 ), allow us to explore the effect of genetic variation on phenotype more thoroughly. Also important is the manner and volume in which raw genetic data are now generated and disseminated under a model of cross-study cooperation and public data deposition, which has been key to overcoming many of the problems that limited the success of candidate gene association studies for complex diseases.
While no genome-wide significant evidence for the involvement of ESR1 variation in CAD risk has been reported in recent GWAS, data from these studies may still provide important information either to support or refute this hypothesis. The fact that many robust new GWAS loci for complex diseases had previously been investigated as candidate genes (eg, LDLR in CAD 21 and several recently confirmed loci for low-density lipoprotein, high-density lipoprotein, and triglycerides 22 ) highlights the importance of revisiting the role of candidate genes in complex diseases. 23 Therefore, in this article, we bring these powerful postgenomic methods and resources to bear on a classical CAD candidate gene to resolve a long-running unanswered question in cardiovascular genetics. For common variation in a genomic region centered on ESR1, we report the results of a large meta-analysis of GWAS of MI and CAD and explore possible sex-specific differences. We also investigate the effect on CAD risk of low-frequency variation in this region.
Materials and Methods

Coronary Artery Disease GWAS Meta-Analysis
The Coronary ARtery DIsease Genome-wide Replication And Metaanalysis (CARDIoGRAM) Consortium was formed with the purpose of identifying novel susceptibility loci for CAD. Briefly, the CARDIoGRAM discovery analysis combined data from 14 published and unpublished primary GWAS in individuals of European ancestry, including 22 233 cases with CAD (stable or unstable coronary events) (30.9% of which were females) and 64 762 controls 21 (58.1% of which were females).
Each primary GWAS performed a logistic regression analysis to test for association between genotyped and imputed (using the HapMap Phase II reference panel 19 ) single-nucleotide polymorphisms (SNPs) and risk of CAD under an additive disease model adjusted for age and sex. (See the online-only Supplemental Methods for a more detailed summary of the genotyping and quality control methods used.)
In this study, we meta-analyzed these study-level results using inverse-variance weighting under a fixed-effects model. We performed a random-effects meta-analysis for SNPs with significant between-study heterogeneity (P-heterogeneity Ͻ0.01), on the basis of Cochran's Q statistic. These analyses were carried out for each of 535 SNPs in a genomic region containing the entire coding and noncoding region of ESR1 (see the online-only Supplemental Table  1 ) and a 50kb region upstream and downstream of the gene (Ϸ547kb; Chr6, 151927808 to 152474406, GRCh37.p1).
Sex-Stratified Analysis
An equivalent analysis to that described above was performed separately for females and males in 13 of the 14 contributing studies (data for the Cohorts for Heart and Aging Research in Genomic Epidemiology [CHARGE] Consortium not available), and the results were meta-analyzed in a similar way. We also formally tested for interaction between each SNP and sex by using the sex-specific effects and variances within each study to estimate those of the SNP-sex interaction term (online-only Supplemental Methods). We then meta-analyzed the results as described for the unstratified analysis.
Fine-Mapping Analysis
Public GWAS Data Sources
To perform fine-mapping studies in the region of interest, we used publicly available genotype and phenotype data from 3 large published GWAS: (1) The Myocardial Infarction Genetics Consortium (MIGen 24 ) is a case-control GWAS consisting of 2967 cases of early-onset MI and 3075 age-and sex-matched controls from 6 international sites in the United States and Europe; (2) The Wellcome Trust Case-Control Consortium (WTCCC 25 ) is a case-control GWAS of CAD consisting of 1988 cases and 5380 controls from the United Kingdom; (3) The Framingham Share Initiative dataset includes genetic data and longitudinal phenotype data, such as incidence of major cardiovascular events, for Ϸ9000 individuals from the Framingham Heart Study (http://www.framinghamheartstudy.org), of which we have included 3717 in the present study (selected to maximize the number of subjects free from cardiovascular disease at baseline who had genetic data and complete follow-up data; 464 events [see below for phenotype definition]; mean follow-up, 13.5 years; online-only Supplementary Appendix 1; Lluís-Ganella et al, unpublished data, 2011).
The phenotypic characteristics of these studies were as follows: MIGen cases were males aged Ͻ50 years or females aged Ͻ60 years who were diagnosed with MI on the basis of autopsy evidence, a combination of chest pain and electrocardiographic evidence, or elevation of cardiac biomarkers; WTCCC cases had a validated history of either MI or coronary revascularization (coronary artery bypass surgery or percutaneous coronary angioplasty) before their 66th birthday; in the Framingham sample, events included incident cases with MI, angina, coronary revascularization, and death because of CAD.
Of the 6042 individuals in the MIGen sample, 2681 were previously included in the CARDIoGRAM discovery meta-analysis. All of the WTCCC cases (NϭϷ1988) and approximately half of the controls (NϭϷ2938) were also included in the CARDIoGRAM meta-analysis, as were many of the individuals in the Framingham sample, as part of the CHARGE Consortium. 26 Genome-wide genotype data and associated phenotype data for the MIGen and Framingham samples were obtained via the database of Genotypes And Phenotypes (dbgap.ncbi.nlm.nih.gov; project num-ber 2392). Data for the WTCCC sample were obtained from the European Genotype Archive (www.ebi.ac.uk/ega) with permission from the WTCCC Data Access Committee (www.wtccc.org.uk).
Genomes Imputation in MIGen, WTCCC, and Framingham
See the online-only Supplemental Figure 1 for a summary of the quality control steps, imputation process, association analyses, and meta-analyses performed for this analysis.
Imputation of untyped genetic variants in individuals from the MIGen, WTCCC, and Framingham samples was performed using IMPUTE2. 17 Imputation was performed for SNPs in the region of interest using a reference panel of phased haplotypes (available from mathgen.stats.ox.ac.uk/impute/impute_v2.html), based on the August 2010 data release from the 1000 Genomes Project 20 (1kG; 566 haplotypes from populations of European ancestry, EUR: CEU, TSI, GBR, FIN, and IBS). As input for this process, we included only directly genotyped SNPs with high call rate (Ն95%) and whose genotype frequencies were in Hardy-Weinberg equilibrium (PՆ10 Ϫ6 ). We carried forward to the analysis stage only those SNPs imputed with high quality (IMPUTE2 INFO metric Ն0.5).
Association and Meta-Analysis of Genotyped and Imputed SNPs in MIGen, WTCCC, and Framingham
A logistic regression analysis of association between allele dosage of imputed and genotyped SNPs and MI/CAD was performed separately in the MIGen, WTCCC, and Framingham samples, with adjustment for sex. Adjustment for age or other clinical covariates was not possible because no further phenotype data were available in all studies; however, the association results in the Framingham and MIGen samples were very similar after additional adjustment for age at event (data not shown), and both the MIGen and WTCCC studies were age-and sex-matched by design. To account for interrelatedness, the analysis of the Framingham sample was also adjusted for the first 2 genetic principal components. 27 The results from these 3 studies were meta-analyzed as described above for the CARDIoGRAM analysis.
Statistical Analysis
Apart from imputation, all analyses were performed using R version 2.11 (packages and functions indicated below by ϽpackageϾ::ϽfunctionϾ). Fixed-and random-effects meta-analyses were performed using rmeta::meta.DSL. Association testing was performed using stats::glm for the case-control studies and survival::coxph for the cohort study.
To account for multiple testing, we used a Bonferroni correction based on the effective number of independent tests in the region of interest to set the threshold for declaring statistical significance (regional significance level). Since many SNPs in the region of interest were not independent, we used the technique proposed by Cheverud 28 to estimate the effective number of independent tests (n eff ; separately for the CARDIoGRAM and fine-mapping results); for this estimation, we computed pairwise linkage disequilibrium (LD) (r 2 ) between all pairs of SNPs in the region of interest using genotype data from the HapMapIIϩIII CEU (344 haplotypes) or 1000 Genomes project EUR (566 haplotypes) reference panels of phased haplotypes for the CARDIoGRAM and fine-mapping analyses, respectively. LD calculations in the region of interest were performed using SNPassoc::LD. 29 We computed the power of each analysis to detect significant associations (online-only Supplemental Methods). Briefly, for each SNP, we computed the power of our analysis to exceed the threshold for declaring statistical significance after adjustment for multiple testing and expressed this power in 2 ways: the minimum odds ratio (OR) the analysis had high or moderate power to detect (Type II errorϭ20% or 50%, respectively); and the power of the analysis to detect each of a series of ORs (eg, 1.05, 1.1, etc.). We 
Results
Meta-Analysis of Genome-Wide Association Studies of CAD (CARDIoGRAM)
Figure A shows a regional plot of global P-values from the CARDIoGRAM meta-analysis for 535 genotyped and imputed (HapMap II) SNPs in the region of interest. Considering a threshold for declaring statistically significant association of PϷ1.02ϫ10 Ϫ4 (n eff Ϸ503), we observed no significant association between common SNPs in this gene and risk of CAD. This analysis had high power (Ϸ80%) to detect ORs of Ն1.10, Ն1.28, and Ն1.33 and moderate power (Ϸ50%) to detect ORs of Ն1.08, Ն1.23, and Ն1.26 for SNPs with MAF Ն0.15, Ն0.05, and Ն0.01, respectively (online-only Supplemental Table 2 ).
The strongest association in this region was observed for a series of 18 SNPs lying within a Ϸ24 kb region of strong LD between noncoding exons E1 and T1 30 
Sex-Stratified Analysis
Under the hypothesis that the effect of genetic variation in ESR1 on CAD risk differs according to sex, we analyzed data from 13 Figure 3) . We used the same criterion for declaring statistical significance as for the unstratified meta-analysis (pϷ1.02ϫ10 Ϫ4 ). In females, we had high power (Ϸ80%) to detect ORs of Ն1.18, Ն1.47, and Ն1.58 and moderate power (Ϸ50%) to detect ORs of Ն1.15, Ն1.37, and Ն1.45 for SNPs with MAF Ն0.15, Ն0.05, and Ն0.01, respectively (online-only Supplemental Table 2 ). In males, we had high power (Ϸ80%) to detect ORs of Ն1.15, Ն1.23, and Ն1.49 and moderate power (Ϸ50%) to detect ORs of Ն1.12, Ն1.18, and Ն1.39 for SNPs with MAF Ն0.15, Ն0.05, and Ն0.01, respectively (onlineonly Supplemental Table 2 ).
One SNP, lying Ϸ35 kb upstream of the most distal noncoding exon (Figure B) , exceeded the threshold for regional significance in the test for interaction between sex and genotype as a predictor of CAD risk (rs9479087, MAF: 0.183 in CARDIoGRAM, P int ϭ1.2ϫ10 Ϫ5 ; online-only Supplemental Figure 3) Figure B) or males (top result: rs9479087, Pϭ0.0026; Figure B ).
Fine-Mapping Analysis
While the density of SNP data in the HapMap II panel (CARDIoGRAM results) for this region is quite high (meanϭ1.15 SNPs/kb), it is possible that some stronger true Regional association results for the ESR1 gene region. Results of CARDIoGRAM global and sex-stratified meta-analysis and fine mapping analysis for a region of chromosome 6 containing the coding and noncoding exons of ESR1 and 50 kb of the upstream and downstream flanking regions (Ϫlog 10 (P-value) shown as black points). Results shown are for a fixed-or random-effects meta-analysis in the absence or presence of between-study heterogeneity, respectively (see Methods). The position of the ESR1 gene is shown at the bottom of the plot (dotted line), with coding and noncoding exons shown as long and short vertical bars, respectively. Regional recombination rate (HapMap II) is shown as a gray line in plot A. A, Regional association plot of global meta-analysis results from the CARDIoGRAM study. B, Regional association plot of sex-stratified meta-analysis results from the CARDIoGRAM study. Results for the test for single-nucleotide polymorphisms (SNP)-sex interaction are shown in the top panel; results for the association test in females and males are shown in the middle and bottom panels, respectively. C, Regional association plot of results from fine-mapping metaanalysis (MIGen, WTCCC, and Framingham studies). Results for SNPs that were previously analyzed in the CARDIoGRAM study are shown as black points (ie, SNPs that were directly genotyped or imputed using a reference panel of haplotypes generated from the Phase II HapMap CEU genotypes). Results for additional SNPs that were imputed using a reference panel of haplotypes generated using data from the 1000 Genomes project (August 2010 release) are shown as gray points. association signals are not captured by these common genotyped and imputed variants. Such signals might be detected by analyzing a higher density map of common and lowfrequency SNPs in this region. To explore this possibility, we imputed Ϸ2500 additional variants from the 1 kG reference panel (Ϸ4.52 SNPs/kb), 1451 of which were imputed with high quality in all 3 samples (Ϸ2.7 SNPs/kb; see the online-only Supplemental Figure 1) . Imputation in the 1 kG panel allowed us to test Ϸ800 additional SNPs within the region of interest that were not included in the CARDIo-GRAM meta-analysis. Newly imputed SNPs had a wide range of MAF, although a large proportion had MAF in the range 0.0 to 0.05 (online-only Supplemental Figure 4) .
After testing for association between SNPs in the 1 kG panel and CAD in the MIGen, WTCCC, and Framingham samples, meta-analyzing the results and correcting for multiple testing (n eff Ϸ1366; ␣ adj Ϸ3.8ϫ10 Ϫ5 ), we observed no globally significant evidence for association in this region ( Figure C ). This analysis had high power (Ϸ80%) to detect ORs of Ն1. 21 
Discussion
In this study, we exploited post-genomic tools and resources to expand on previous candidate association studies of ESR1 in 2 main ways: (1) we analyzed a large number of common and uncommon genetic variants in the coding, noncoding, and flanking regions of the gene, capturing a large proportion of the genetic variation throughout the gene and its regulatory regions; (2) we performed these analyses in large samples of up to Ϸ85 000 individuals representing multiple populations of European descent, which increases our power to detect subtle risk effects.
Despite this study's power to detect case-control differences in CAD risk of as low as 10% for a broad range of genetic variation throughout this region, we found no evidence of involvement of ESR1 in modifying CAD risk either at the population level or as a function of sex. We consider these results surprising, given ER␣'s central role in estrogen and androgen signaling, its widespread expression in vascular tissues, and the importance of sex for CAD risk.
After age, male sex remains the most important independent cardiovascular risk factor (CVRF), and has a far greater impact on total risk than other important risk factors, such as smoking, lipid profile, and diabetes. The physiological basis of this sex difference remains unclear, and limited research into this question has been carried out, compared with that for other risk factors, mainly because sex is nonmodifiable; however, rather than considering male sex as a nonmodifiable cause of increased CAD risk, it is important to remember that sex is a simple mendelian trait determined by the presence or absence of a single gene, SRY, which is inherited on the Y chromosome in males. Since, as far as we are aware, no evidence of association between CAD and SRY has been reported, it is not appropriate to consider sex as being causally associated with CAD risk. Rather, sex is a trait that is strongly associated with CAD risk via unknown and potentially modifiable factors (eg, physiological, environmental, behavioral factors, etc), whose effects we can partly capture by using sex as a proxy variable. It is important to identify and understand these factors because the ability to modify even a fraction of sex-associated CAD risk might have a marked impact on prevention, possibly more so than by modifying other CVRFs.
All of the loci identified by GWAS to date as being associated with CAD risk are located on autosomes, and it seems likely that most or all of the loci that explain the remaining heritability of CAD risk will also be autosomal. Consequently, these loci are in linkage equilibrium with SRY and have equal genotype frequencies in males and females. This leads us to the simple but important conclusion that differences in CAD risk between sex cannot be directly caused by genetic factors but can only arise because of an interaction between sex and other processes associated with risk. Consequently, the present study, like all association studies of primary autosomal genetic variation, does not attempt to explain differences in risk between sex. Instead, we search for population-level differences in CAD risk that are driven by ESR1 variation and whose effects may or may not be different among females compared with males (ie, that interact with sex).
Over the past decade, candidate-gene association studies 31, 13 have reported generally inconsistent results regarding the role of ESR1 genetic variation in CAD risk. An initial meta-analysis including Ϸ7000 individuals supported association, 12 but this result was not upheld by 2 subsequent meta-analyses representing Ϸ16 000 13 and Ϸ32 000 14 individuals; however, these studies have been restricted to a very limited number of SNPs (especially rs2234693 and rs9340799, previously known as the PvuII and XbaI variants, which lie in Intron 1) out of the thousands now known to lie within the gene region. We estimate that the 4 most widely studied variants collectively capture (with r 2 Ն0.8) only Ϸ2% of the 1450 SNPs tested in our study (data not shown). Therefore, although recent reports have found no evidence of association between ESR1 variation and CAD risk, 13, 14 this question remains unanswered until a more complete survey of the gene is carried out. The potential gain to be made from this is illustrated by recent advances in understanding ESR1's role in modulating bone mineral density and fracture risk, phenotypes that show intriguingly similar patterns of sexspecific and menopause-related risk to those observed for cardiovascular risk. While candidate gene studies of the role of ESR1 variation in bone mineral density and fracture risk also examined a limited range of genetic variation and obtained similarly inconsistent results, 32,33 a large meta-analysis of several GWAS subsequently confirmed the involvement of ESR1 variation in modulating these phenotypes, 34 with highly significant evidence for association in the upstream noncoding regulatory region of the gene, in stark contrast with the lack of association we have observed for CAD.
In the discovery stage of the CARDIoGRAM study, the direction of effect of the lead SNP was largely consistent across the contributing studies (online-only Supplemental Figure 1 ) but fell well short of the threshold for regional statistical significance. The region of high LD containing this SNP was located within the 5Ј regulatory region but did not coincide with the previously reported signal for bone mineral density and fracture risk. 34 We found no broadly convincing evidence of association between ESR1 variation and CAD risk as a function of sex. Although the P-value of the sex interaction test for 1 SNP exceeded the significance threshold set, with opposing effects observed among males and females, this variant was not significantly associated with CAD risk in either sex considered separately (online-only Supplemental Figure 3 ). Considering the additional fact that this variant lies at a considerable distance from the regulatory (Ϸ35 kb) and coding (Ϸ186 kb) regions of the gene, we feel that these results do not provide strong evidence of a robust sex-specific association at this locus. In addition to sex, another potential modifier of the putative association between ESR1 variation and CAD risk is menopausal status among women. Although we were unable to investigate this issue directly, we provide some initial data on this question based on age data from the MIGen study, and we find no evidence of significantly different effects of ESR1 variation on cardiovascular risk as a function of menopausal status (see the online-only Supplemental Note).
In the fine-mapping analysis, imputation using data from the 1000 Genomes Project allowed us to analyze a much denser map of common variants in the region (online-only Supplemental Figure 4 ) and especially to explore the role of variants with frequencies below 0.05, which are under-represented in haplotype panels based on data from the HapMap project but which are a potentially important source of risk variance in complex diseases 35, 36 ; however, we found no additional evidence of association with CAD risk for any of these additional variants.
We highlight the fact that this study is well-powered to detect genetic risk effects with sizes and frequencies that are generally plausible for common complex diseases. For example, in the CARDIoGRAM discovery analysis, we have high power (Ϸ80%) to detect common variants with MAF Ն0.15 that carry risk effects as low as OR Ϸ1.1 and low-frequency variants (0.01ՅMAF Յ0.05) that carry risk effects of OR Ϸ1.3. In addition, the fine mapping analysis was also powered to detect associations for rare imputed variants with MAF Յ0.01 and effect sizes of approximately ORϷ3. Weaker and/or rarer risk effects than these are likely to have limited clinical relevance at the population level. In these power computations, we used stringent statistical significance thresholds that account for multiple testing (see the onlineonly Supplemental Methods).
The most likely explanation for lack of observable association in this analysis is that no true association exists in this gene, although we note the following limitations in this study's ability to draw this conclusion: First, this study does not address this question in populations with non-European ancestry. Second, some truly associated variants in this gene may not have been detected by this study, although these are unlikely to be simple primary sequence variants with low allelic diversity, such as common or uncommon SNPs, low-copy number polymorphisms, or insertions/deletions. This analysis was also unable to detect very weak or very rare effects (online-only Supplemental Table 2 ). Third, this study cannot address the role of other potentially relevant forms of variation related to ER␣, such as epistasis or epigenetic (eg, promoter methylation), post-transcriptional, or posttranslational variation; however, if such variation exists, it is likely to be largely independent of primary sequence variation. Fourth, this study suggests that menopausal status does not modify the effect of ESR1 variation on female CAD risk but cannot discount this possibility because of the size and imprecise design of that analysis. Fifth, these analyses were not adjusted for classical CVRFs, although a true SNP-CAD association would only be masked by confounding if the SNP had opposing effects on CAD risk and CVRF profile, which seems unlikely. Sixth, most of the studies included in these meta-analyses had a case-control design, which could lead to a bias against the discovery of variants that reduce survival.
Finally, it is important to note that we have analyzed the genetic variation in only 1 of the genes that encode components of the steroid sex hormone system. A more thorough exploration of this system may help to clarify the role of this system in the pathophysiology of coronary risk.
Conclusions
In conclusion, on the basis of data from a large number of subjects representing multiple samples from several populations, we find no evidence for involvement of common or uncommon genetic variation in the coding, noncoding, or flanking regions of the ESR1 gene in modifying risk of CAD, irrespective of sex; however, data from observational studies and subanalysis of clinical trials continue to support the involvement of the steroid hormone system in modulating CAD risk. Therefore, we consider that the next step in exploring the role of the sex hormone biosynthesis system in modulating CAD risk should initially be to prioritize the investigation of other genes within this system.
